Phase 1/2 × Myelodysplastic-Myeloproliferative Diseases × Tacrolimus × Clear all
NCT00555048 2017-05-24

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
1 enrolled 5 charts
NCT00089037 2011-07-15

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 1/2 Completed